<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371252</url>
  </required_header>
  <id_info>
    <org_study_id>150/2557(EC3)</org_study_id>
    <nct_id>NCT02371252</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment</brief_title>
  <official_title>Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis is a common disease defined as a decrease in bone mass and strength which&#xD;
      increases risk of fragility fractures. This disorder may affecting health in many adults&#xD;
      which causing disability, morbidity, and mortality. Current first-line medical therapy is&#xD;
      bisphosphonates which alendronate is one of the most widely used. However, expenditure on&#xD;
      medicines is one of the major problem of inadequate access to treatment.&#xD;
&#xD;
      The investigators hypothesized that generic alendronate will have the same clinical efficacy&#xD;
      as the brand formulation. Therefore, the result of this study is extremely crucial. If&#xD;
      adequate efficacy of generic alendronate could be established and if it affords the same&#xD;
      safety profile as those of brand alendronate, the use of generic alendronate could then be&#xD;
      recommended.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is a common disease which estimated that over 200 million people worldwide are&#xD;
      suffered. The prevalence is continuing to escalate with the increasingly elderly population.&#xD;
      The risk of fragility fractures in elder over age 50 is approximately 50% in women and 20% in&#xD;
      men.&#xD;
&#xD;
      Current first-line medical therapy is bisphosphonates which alendronate is one of the most&#xD;
      widely used. However, expenditure on medicines is one of the major problem of inadequate&#xD;
      access to treatment. Generally, insurances and health care providers prefer physicians to&#xD;
      prescribe generic instead of brand drug, due to its lower costs. However, clinical&#xD;
      information on bone mineral density (BMD), fracture reduction and side effects with new&#xD;
      generic alendronate is limited.&#xD;
&#xD;
      The objective of this study is to evaluate the efficacy and safety of a new generic&#xD;
      alendronate (Bonmax®) comparing to brand alendronate (Fosamax®). The efficacy of generic&#xD;
      alendronate will be determined by measuring the percent changes of bone mineral densities at&#xD;
      lumbar spine and total hip after 1 year of treatment and then comparing to those changes in&#xD;
      the brand alendronate group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) at Total Hip</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Resorption Markers (Serum CTX)</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>Percent changes of serum bone markers (serum CTX) from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Formation Marker (Serum PINP)</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Original alendronate (Fosamax)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic alendronate (Bonmax)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic alendronate</intervention_name>
    <description>The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.</description>
    <arm_group_label>Generic alendronate (Bonmax)</arm_group_label>
    <other_name>Bonmax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients who are postmenopausal women or men who aged older than 50&#xD;
        years and meet the indications for osteoporosis treatment according to the Thai&#xD;
        Osteoporosis Foundation's 2010 treatment guidelines.&#xD;
&#xD;
          -  History of spinal or hip fractures with low energy trauma.&#xD;
&#xD;
          -  BMD by Dual energy X-ray absorptiometry (DXA) scan with T-score ≤ -2.5 at the femoral&#xD;
             neck, total hip, or L1-L4 spine.&#xD;
&#xD;
          -  BMD by DXA scan with T-score between -1 and -2.5 at the femoral neck, total hip, or&#xD;
             L1-L4 spine and a 10-year hip fracture probability ≥ 3% or a 10-year major&#xD;
             osteoporosis-related fracture probability ≥ 20% based on Fracture risk assessment tool&#xD;
             (FRAX)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have contraindications to use bisphosphonates e.g. gastroesophageal&#xD;
             reflux disease or drug allergy to bisphosphonates&#xD;
&#xD;
          -  Patients with an abnormality of serum calcium levels (more than 10.2 mg/dl or less&#xD;
             than 8.7 mg/dl)&#xD;
&#xD;
          -  Patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m2&#xD;
&#xD;
          -  Patients with metabolic bone diseases such as Paget's disease, hyperparathyroidism,&#xD;
             etc.&#xD;
&#xD;
          -  Patients who were received anti-osteoporotic drugs during the past 1 year.&#xD;
&#xD;
          -  Patients who currently taking steroids, hormone replacement therapy, or selective&#xD;
             estrogen receptor modulators (SERMs) within 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aasis Unnanuntana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>September 1, 2021</results_first_submitted>
  <results_first_submitted_qc>September 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>Alendronate</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Bone markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Original Alendronate (Fosamax)</title>
          <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
        </group>
        <group group_id="P2">
          <title>Generic Alendronate (Bonmax)</title>
          <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.&#xD;
Generic alendronate: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Original Alendronate (Fosamax)</title>
          <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
        </group>
        <group group_id="B2">
          <title>Generic Alendronate (Bonmax)</title>
          <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.&#xD;
Generic alendronate: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.7" spread="9.7"/>
                    <measurement group_id="B2" value="73.7" spread="7.2"/>
                    <measurement group_id="B3" value="73.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</title>
        <description>Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
        <time_frame>1 year after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Original Alendronate (Fosamax)</title>
            <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
          </group>
          <group group_id="O2">
            <title>Generic Alendronate (Bonmax)</title>
            <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.&#xD;
Generic alendronate: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</title>
          <description>Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="6.39"/>
                    <measurement group_id="O2" value="5.39" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density (BMD) at Total Hip</title>
        <description>Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
        <time_frame>1 year after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Original Alendronate (Fosamax)</title>
            <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
          </group>
          <group group_id="O2">
            <title>Generic Alendronate (Bonmax)</title>
            <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.&#xD;
Generic alendronate: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) at Total Hip</title>
          <description>Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="4.56"/>
                    <measurement group_id="O2" value="2.52" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Resorption Markers (Serum CTX)</title>
        <description>Percent changes of serum bone markers (serum CTX) from baseline to 1-year after treatment will be compared and analysed between 2 groups.</description>
        <time_frame>1 year after treatment</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Formation Marker (Serum PINP)</title>
        <time_frame>1 year after treatment</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Original Alendronate (Fosamax)</title>
          <description>The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
        </group>
        <group group_id="E2">
          <title>Generic Alendronate (Bonmax)</title>
          <description>The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="70" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="70" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia and arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small sample sizes and only one generic brand of bisphosphonate was used.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Aasis Unnanuntana</name_or_title>
      <organization>Mahidol University</organization>
      <phone>+66836871159</phone>
      <email>uaasis@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

